Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
KETOCONAZOLE - Risk of Potentially Fatal Liver Toxicity - For Health Professionals
- Starting date:
- June 19, 2013
- Posting date:
- June 19, 2013
- Type of communication:
- Dear Healthcare Professional Letter
- Source of recall:
- Health Canada
- Important Safety Information
- Healthcare Professionals
- Identification number:
This is duplicated text of a letter from Apotex Inc. and Teva Canada Limited. Contact the company for a copy of any references, attachments or enclosures.
Health Canada Endorsed Important Safety Information on KETOCONAZOLE
June 19, 2013
Subject: KETOCONAZOLE and the Risk of potentially Fatal Liver Toxicity
Dear Health Care Professional,
The manufacturers of KETOCONAZOLE, in collaboration with Health Canada, would like to inform you of revisions to the Product Monograph for KETOCONAZOLE regarding the risk of potentially fatal liver toxicity.
KETOCONAZOLE has been associated with rare cases of serious hepatotoxicity including liver failure and death. This risk was also observed in patients with no pre-existing liver disease and no serious underlying medical conditions. Hepatotoxicity and death have been reported to occur at recommended doses and with treatment courses longer than 10 days.
The Warnings’ sections of the Product Monographs have been updated to include the following additional instructions:
- KETOCONAZOLE tablets are indicated for the treatment of serious or life threatening systemic fungal infections and should not be considered for mild to moderate infections.
- Oral KETOCONAZOLE has been associated with hepatic toxicity, including cases with fatal outcomes.
- Liver function tests should be performed in all patients before starting treatment, at week 2 and 4, and monthly thereafter.
- Treatment should be stopped if liver parameters are elevated (> 3 times the normal limit) or if patients develop clinical signs or symptoms consistent with liver disease such as anorexia, nausea, vomiting, jaundice, fatigue, abdominal pain, dark urine, or pale stools.
Healthcare practitioners should consider the risk of fatal liver toxicity with KETOCONAZOLE when prescribing antifungal treatment for patients who are already at risk for liver toxicity. Patients using KETOCONAZOLE concurrently with potentially hepatotoxic drugs should be carefully monitored, especially in those expected to be on prolonged therapy or at risk for hepatotoxicity.
The profile of KETOCONAZOLE is continually monitored and reassessed as new information becomes available through the literature, clinical studies, spontaneous reports, and safety database searches.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious liver toxicity or other serious or unexpected adverse reactions in patients receiving KETOCONAZOLE should be reported to either of the respective manufacturers (Apotex Inc. or Teva Canada Limited) or Health Canada.
150 Signet Drive
Teva Canada Limited
30 Novopharm Court
Phone: 1-800-268-4127 Ext. 1255005 (English) or 1-877-777-9117 (French)
To correct your mailing address or fax number, contact Apotex Inc. or Teva Canada Limited.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
- Calling toll-free at 1-866-234-2345; or
- Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
original signed by
Director, Global Medical Affairs
Director, Medical Affairs
Teva Canada Limited
- Apo-Ketoconazole Product Monograph. Apotex Inc. 2013.
- Novo-Ketoconazole Product Monograph. Teva Canada Limited. 2013.
- L. A. Garcia Rodriguez, A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999, 48, 847–852.
- Date modified: